{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:45:01Z","timestamp":1761662701891,"version":"3.40.4"},"reference-count":25,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[2009]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt;&lt;i&gt;Streptococcus pneumoniae &lt;\/i&gt;infection is an important cause of morbidity and mortality. The recommendations to use expanded-spectrum \u03b2-lactam drugs for patients with community-acquired pneumonia derived from the growing prevalence of penicillin-resistant pneumococci. Controversy exists regarding the use of second generation cephalosporins for empirical treatment of community-acquired pneumonia. &lt;i&gt;Methods:&lt;\/i&gt; In a retrospective study, 31 adult patients with pneumococcal pneumonia and bacteremia caused by &lt;i&gt;S. pneumoniae&lt;\/i&gt; that was intermediately resistant to penicillin were compared with 31 control patients with similar infection caused by penicillin-susceptible pneumococci. All patients were treated empirically with cefuroxime, alone or in combination with other antibiotics. Morbidity and mortality were studied. &lt;i&gt;Results:&lt;\/i&gt; All unsusceptible pneumococci isolates were intermediately resistant to penicillin. No cases of fully resistant pneumococci were isolated from blood cultures in our hospital. Two factors were significantly associated with non-susceptibility to penicillin: hematologic malignancy and immunosuppression. No significant difference in morbidity or mortality was detected between the 2 groups, and penicillin minimum inhibitory concentration was not found to be a factor associated with mortality. &lt;i&gt;Conclusions:&lt;\/i&gt; Patients with pneumococcal pneumonia caused by intermediately resistant pneumococci can be empirically treated with cefuroxime. In regions where fully resistant pneumococci are rare, the use of a second generation cephalosporin for empiric treatment of community-acquired pneumonia may be appropriate.<\/jats:p>","DOI":"10.1159\/000192393","type":"journal-article","created":{"date-parts":[[2009,1,20]],"date-time":"2009-01-20T08:53:22Z","timestamp":1232441602000},"page":"97-104","source":"Crossref","is-referenced-by-count":2,"title":["Cefuroxime for Empiric Treatment of Community-Acquired Pneumococcal Pneumonia: Is There a Generation Gap?"],"prefix":"10.1159","volume":"55","author":[{"given":"Yonit","family":"Wiener-Well","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Raveh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yechiel","family":"Schlesinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amos M.","family":"Yinnon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Rudensky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,1,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM197101282840403"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016%2FS0140-6736%2877%2992892-6"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038%2Fnm839"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2Fdkg321"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1128%2FJCM.41.12.5541-5545.2003"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159%2F000080692"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1086%2F380488"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1378%2Fchest.125.5.1888"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001%2Farchinte.160.10.1399"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001%2Farchinte.161.21.2538"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM199508243330802"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1086%2F377534"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1128%2FJCM.39.1.367-369.2001"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1469-0691.8.s.3.3.x"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1086%2F513635"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1086%2F520209"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2105%2FAJPH.90.2.223"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1086%2F313716"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1086%2F324526"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1159%2F000118659"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1086%2F511159"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1086%2F516284"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1378%2Fchest.112.6.1657"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1469-0691.2004.00872.x"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1086%2F420821"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/192393","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/192393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T23:19:59Z","timestamp":1745450399000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000192393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2009,2,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000192393","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"type":"print","value":"0009-3157"},{"type":"electronic","value":"1421-9794"}],"subject":[],"published":{"date-parts":[[2009]]}}}